NewAmsterdam Pharma Doses First Patient in Phase 3 BROADWAY Trial of Obicetrapib in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) and/or Established Atherosclerotic Cardiovascular Disease (ASCVD)

“We are thrilled to initiate our Phase 3 BROADWAY trial,” said Michael Davidson, MD, chief executive officer of NewAmsterdam Pharma. “With this study, we are confident that we will continue generating compelling data around the benefit of obicetrapib—a simple, low-dose, once daily oral therapy—for patients at risk for cardiometabolic diseases. We look forward to providing additional updates as our clinical program progresses.”

The primary objective of the BROADWAY trial is to evaluate the effect of obicetrapib on LDL-c levels at day 84. Secondary objectives include evaluating the effect of obicetrapib on apolipoprotein B (ApoB), non-high density lipoprotein cholesterol (HDL-c), HDL-c, total cholesterol and triglycerides at day 84, and on LDL-c levels at days 180 and 365. The trial will also be evaluating the safety and tolerability profile of obicetrapib.

A total of 2,400 patients will be randomized to placebo or 10 mg obicetrapib dosed as a once daily oral treatment for a 52-week treatment period. Enrollment is expected to be completed in the fourth quarter of 2022.

About Obicetrapib
Obicetrapib is a selective cholesteryl ester transfer protein (CETP) inhibitor in development for lowering low-density lipoprotein cholesterol (LDL-c) and preventing major adverse cardiovascular events. More than 100 million people globally are not achieving LDL-c goals despite the current available standard of care. Obicetrapib was previously tested in ROSE and TULIP (published in The Lancet), randomized double-blind, placebo-controlled Phase 2 trials. The latest data, from the ROSE trial presented in November 2021 at the AHA Scientific Sessions, showed that both obicetrapib 5 mg and 10 mg dosed as a once daily oral treatment reduced median LDL-c levels by 42% and 51% from baseline, respectively, in patients on high-intensity statin therapy and were well tolerated, with no serious adverse effects in the two cohorts and two serious AEs in the placebo arm.

About NewAmsterdam Pharma
Founded in 2019 by the venture capital firm Forbion and John Kastelein, NewAmsterdam Pharma is a privately held, clinical-stage company focused on the research and development of transformative therapies for metabolic diseases. Its mission is to improve patient care in populations. In April 2020, NewAmsterdam acquired Dezima Pharma from Amgen, including all rights for obicetrapib (formerly AMG 899, now TA-8995) a selective cholesteryl ester transfer protein (CETP) inhibitor. In January 2021, NewAmsterdam Pharma closed a $196M (€161M) Series A financing led by Morningside Ventures and Ascendant BioCapital with participation from Forbion, Kaiser Foundation Hospitals, BVF Partners L.P., Population Health Partners, LSP Dementia Fund, Peter Thiel, Janus Henderson Investors, Medpace, GL Capital, JVC Investment Partners, and Presight Capital. The Company is investigating obicetrapib as the preferred LDL-c lowering therapy for patients with ASCVD/FH on maximally tolerated statin therapy as well as for the treatment of Alzheimer’s disease and diabetes. NewAmsterdam Pharma is headquartered in Naarden, The Netherlands. For more information, please visit: www.newamsterdampharma.com